Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435172 | 1.00 | PDE4B (0.56) | PDE4BPDE4DPDE4ATAS1R3TAS1R1 | |
| SCHEMBL5546898 | 0.91 | PDE4B (0.47) | PDE4BPDE4DPDE4ATAS1R3TAS1R1 | |
| SCHEMBL5552570 | 0.89 | PDE4B (0.48) | PDE4BPDE4DPDE4ATAS1R3TAS1R1 | |
| SCHEMBL8303245 | 0.88 | PDE4B (0.50) | PDE4BPDE4DPDE4ATYK2NPC1 | |
| SCHEMBL13929105 | 0.88 | PDE4B (0.50) | PDE4BPDE4DPDE4ATYK2NPC1 | |
| SCHEMBL4182884 | 0.88 | PDE4B (0.50) | PDE4BPDE4DPDE4ATYK2NPC1 | |
| SCHEMBL5547933 | 0.87 | PDE4B (0.55) | PDE4BPDE4DPDE4AKCNH2CRHR1 | |
| SCHEMBL4191409 | 0.86 | PDE4B (0.50) | PDE4BPDE4DPDE4ATAS1R3TAS1R1 | |
| SCHEMBL4191242 | 0.85 | PDE4B (0.49) | PDE4BPDE4DPDE4ATAS1R3TAS1R1 | |
| SCHEMBL8302740 | 0.85 | PDE4B (0.46) | PDE4BPDE4DPDE4ATYK2CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194635-A1 | Crystalline Forms of Cis-5-Fluoro-N-[4-(2-Hydroxy-4-Methylbenzamido) Cyclohexyl]-2-(Tetrahydrothiopyran-4-Yloxy) Nicotinamide | PFIZER INC. (US) | 2008-08-14 | — | — | US | claimed |
| EP-1844040-A1 | CRYSTALLINE FORMS OF CIS-5-FLUORO-N-[4-(2-HYDROXY-4-METHYLBENZAMIDO)CYCLOHEXYL]-2-(TETRAHYDROTHIOPYRAN-4-YLOXY)NICOTINAMIDE | Pfizer Limited (GB) | 2007-10-17 | — | — | EP | claimed |
| WO-2006077497-A1 | CRYSTALLINE FORMS CIS-5-FLUORO-N-[4-(2-HYDROXY-4-METHYLBENZAMIDO) CYCLOHEXYL]-2-(TETRAHYDROTHIOPYRAN-A-YLOXY) NICOTINAMIDE | PFIZER LIMITED (GB) | 2006-07-27 | — | — | WO | claimed |
| EP-1683795-A1 | Crystalline forms of cis-5-fluoro-N-¬4-(2-hydroxy-4-methylbenzamido)cyclohexyl|-2-(tetrahydrothiopyran-4-yloxy)nicotinamide | Pfizer Limited (GB) | 2006-07-26 | — | — | EP | claimed |
| US-20080194635-A1 | Crystalline Forms of Cis-5-Fluoro-N-[4-(2-Hydroxy-4-Methylbenzamido) Cyclohexyl]-2-(Tetrahydrothiopyran-4-Yloxy) Nicotinamide | PFIZER INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194635-A1 | Crystalline Forms of Cis-5-Fluoro-N-[4-(2-Hydroxy-4-Methylbenzamido) Cyclohexyl]-2-(Tetrahydrothiopyran-4-Yloxy) Nicotinamide | PFIZER INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194635-A1 | Crystalline Forms of Cis-5-Fluoro-N-[4-(2-Hydroxy-4-Methylbenzamido) Cyclohexyl]-2-(Tetrahydrothiopyran-4-Yloxy) Nicotinamide | PFIZER INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194635-A1 | Crystalline Forms of Cis-5-Fluoro-N-[4-(2-Hydroxy-4-Methylbenzamido) Cyclohexyl]-2-(Tetrahydrothiopyran-4-Yloxy) Nicotinamide | PFIZER INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1844040-A1 | CRYSTALLINE FORMS OF CIS-5-FLUORO-N-[4-(2-HYDROXY-4-METHYLBENZAMIDO)CYCLOHEXYL]-2-(TETRAHYDROTHIOPYRAN-4-YLOXY)NICOTINAMIDE | Pfizer Limited (GB) | 2007-10-17 | — | — | EP | disclosed |
| JP-2006199700-A | CRYSTAL FORM | PFIZER LTD | 2006-08-03 | — | — | JP | disclosed |
| EP-1683795-A1 | Crystalline forms of cis-5-fluoro-N-¬4-(2-hydroxy-4-methylbenzamido)cyclohexyl|-2-(tetrahydrothiopyran-4-yloxy)nicotinamide | Pfizer Limited (GB) | 2006-07-26 | — | — | EP | disclosed |
| EP-1683795-A1 | Crystalline forms of cis-5-fluoro-N-¬4-(2-hydroxy-4-methylbenzamido)cyclohexyl|-2-(tetrahydrothiopyran-4-yloxy)nicotinamide | Pfizer Limited (GB) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194635-A1 | Crystalline Forms of Cis-5-Fluoro-N-[4-(2-Hydroxy-4-Methylbenzamido) Cyclohexyl]-2-(Tetrahydrothiopyran-4-Yloxy) Nicotinamide | SIRT5, NAMPT, SIRT4 | PDE4B 1081/4885PDE4D 1288/4885PDE4A 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.